December 10, 2017 / 10:03 PM / 2 years ago

BRIEF-‍Verastem Announces Clinical Data From Pivotal Phase 3 Duo Study​

Dec 10 (Reuters) - Verastem Inc:

* ‍VERASTEM ANNOUNCES CLINICAL DATA FROM PIVOTAL PHASE 3 DUO™ STUDY​

* ‍DUO STUDY ACHIEVES PRIMARY ENDPOINT, DEMONSTRATING STATISTICALLY SIGNIFICANT IMPROVEMENT IN PFS FOR DUVELISIB VERSUS OFATUMUMAB​

* ‍PLANS TO SUBMIT A NDA TO U.S. FDA REQUESTING FULL APPROVAL OF DUVELISIB​

* ‍PLANS TO SUBMIT ACCELERATED APPROVAL OF DUVELISIB FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY FL ​

* ‍EXPECTS TO SUBMIT DUVELISIB NDA DURING Q1 OF 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below